Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | KDM4B | O94953 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417708 | 0.68 | PDPK1 (0.52) | RAB9ASMN1; SMN2ALDH1A1HPGDKDM4A | |
| SCHEMBL16815323 | 0.67 | CYP1A2 (0.60) | CYP1A2TMIGD3CYP2C9ADORA1LMNA | |
| SCHEMBL4877959 | 0.65 | KDM4E (0.45) | CYP1A2CYP2C9LMNARAB9ASMN1; SMN2 | |
| SCHEMBL9549938 | 0.65 | CYP1A2 (0.63) | CYP1A2TMIGD3CYP2C9ADORA1LMNA | |
| SCHEMBL925775 | 0.64 | ELANE (0.30) | — | |
| SCHEMBL4755546 | 0.62 | KDM5A (0.49) | LMNASMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL15628661 | 0.62 | PDPK1 (0.58) | CYP1A2TMIGD3CYP2C9ADORA1LMNA | |
| SCHEMBL20513836 | 0.62 | CYP1A2 (0.58) | CYP1A2TMIGD3CYP2C9ADORA1LMNA | |
| SCHEMBL3108511 | 0.62 | TMIGD3 (1.00) | CYP1A2TMIGD3CYP2C9ADORA1LMNA | |
| SCHEMBL21895453 | 0.62 | PARP1 (0.54) | LMNARAB9ASMN1; SMN2TSHRADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | claimed |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-15 | — | — | US | disclosed |
| US-10626122-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180362541-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-20 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010014930-A2 | THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009001214-A2 | THIENO[2,3-D]PYRIMIDIN-4(3H)-ONE, ISOXAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE AND ISOTHIAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009001214-A2 | THIENO[2,3-D]PYRIMIDIN-4(3H)-ONE, ISOXAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE AND ISOTHIAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20070249636-A1 | Selected Fused Heterocyclics and Uses Thereof | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| EP-0733633-B1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165183-A1 | PIPERIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | CYP1A2 2609/4885TMIGD3 2933/4885CYP2C9 1783/4885 |
| US-20070249636-A1 | Selected Fused Heterocyclics and Uses Thereof | SDHA, CYP11B2, NQO1 | CYP1A2 37/4885TMIGD3 4497/4885CYP2C9 87/4885 |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | CYP1A2 1963/4885TMIGD3 2089/4885CYP2C9 2214/4885 |
| US-10626122-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | CYP1A2 1963/4885TMIGD3 2089/4885CYP2C9 2214/4885 |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | RB1, CDK19, PRMT9 | CYP1A2 416/4885TMIGD3 3362/4885CYP2C9 40/4885 |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | CYP1A2 1963/4885TMIGD3 2089/4885CYP2C9 2214/4885 |
| US-20180362541-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | CYP1A2 1963/4885TMIGD3 2089/4885CYP2C9 2214/4885 |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | RB1, CDK19, PRMT9 | CYP1A2 416/4885TMIGD3 3362/4885CYP2C9 40/4885 |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | DHFR, DPYD, TYMS | CYP1A2 330/4885TMIGD3 4020/4885CYP2C9 461/4885 |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | SDHA, CYP11B2, NQO1 | CYP1A2 37/4885TMIGD3 4497/4885CYP2C9 87/4885 |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | CYP1A2 1963/4885TMIGD3 2089/4885CYP2C9 2214/4885 |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | CYP11B2, HCCS, CYP11B1 | CYP1A2 15/4885TMIGD3 4717/4885CYP2C9 36/4885 |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | CYP1A2 1963/4885TMIGD3 2089/4885CYP2C9 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.